Blue Light Photodynamic Therapy Illuminator
Model 4170

BLU-U® - Unique and Patented Design

The BLU-U for actinic keratoses (AKs) - optimal design for treating AKs on the face or scalp

Clinical Output

  • As you know, AKs reside within the epidermis which is less than 2 mm thick.1 The BLU-U blue light penetrates up to 2 mm of skin.2  
  • The BLU-U also has enough energy to produce a photodynamic response. In our Phase II study the maximum clinical response with Levulan® Kerastick® (aminolevulinic acid HCl) Topical Solution, 20% was produced at 10 J/cm2 at 1000 seconds.
  • Finally, BLU-U output is matched to the highest absorption peak of PpIX.3  It’s peak wavelength occurs at 417 ±5 nm and the maximum absorption peak for porphyrins occurs at 410 nm.3,4


Design Features

The BLU-U is designed to deliver a uniform light dose and stable wavelength to an entire treatment area.3

  • The large U-shaped design and tube spacing allows for the treatment of an entire face or scalp while delivering a consistent light dose all the way to the treatment edges.
  • The unit is designed with a stainless steel reflective wall behind the tubes to minimize loss of light within the U-shaped treatment area.
  • Light tubes are spaced much closer together at the top and bottom than in the middle to compensate for light falloff in this area.


The BLU-U is designed to deliver a consistent light dose.3

  • The phosphor in the fluorescent tubes produces a very stable and cost-effective wavelength.
  • The BLU-U contains a microprocessor that continuously monitors and adjusts light output to maintain dose stability from the first to the last treatment. 

Use with eyewear that blocks light of at least 500 nm and shorter with an optical density of two or greater. BLU-U does not emit UVA or UVB light. 

BLU-U for Acne - Innovative, Simple, Effective

The BLU-U offers effective, non-invasive and pain-free blue light treatment for moderate inflammatory acne vulgaris. Narrow band blue light causes a photodynamic effect within the pilosebaceous gland that kills P. acnes, the bacteria primarily responsible for acne vulgaris. When used in a series of brief (approximately 17 minutes) exposure sessions, it provides a simple, non-invasive treatment regimen. BLU-U treatments can be a primary treatment, an alternative to pharmaceuticals and topicals, or an adjunct to skin care programs.


Blu-u Diagram




2 MacCormack, MA. Photodynamic Therapy. Advances in Dermatology. 2006;22:219-258.

3 Data on file, DUSA Pharmaceuticals, Inc.

4 Taub, AF. Photodynamic Therapy in Dermatology; History and Horizons. J. Drugs Dermatol. 2004;3:S8-S25.


Important Risk Information
LEVULAN KERASTICK plus blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.

Application of LEVULAN KERASTICK should involve either scalp or face lesions, but not both simultaneously. LEVULAN KERASTICK should not be applied to the periorbital area or allowed to contact ocular or mucosal surfaces. Excessive irritation may be experienced if this product is applied under occlusion.

Contraindicated in patients with cutaneous photosensitivity at wavelengths of 400-450 nm, porphyria, or known allergies to porphyrins, and in patients with known sensitivity to any of the components of the LEVULAN KERASTICK for Topical Solution.

LEVULAN KERASTICK has not been tested on patients with inherited or acquired coagulation defects. It is possible that concomitant use of other known photosensitizing agents might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK.

Patients should avoid exposure of the photosensitive treatment sites to sunlight or bright indoor light for at least 40 hours after LEVULAN KERASTICK application. Exposure may result in a stinging and/or burning sensation and may cause erythema or edema of the lesions. Patients should protect treated lesions from the sun by wearing a wide-brimmed hat or similar head covering of light-opaque material. Sunscreens will not protect against photosensitivity reactions caused by visible light.

Transient local symptoms of stinging and/or burning, itching, erythema, and edema were observed in all clinical studies. Severe stinging and/or burning at one or more lesions being treated was reported by at least 50% of patients at some time during treatment. However, less than 3% of patients discontinued light treatment due to stinging and/or burning.

During light treatment, both patients and medical personnel should be provided with blue blocking protective eyewear, as specified in the BLU-U operating instructions to minimize ocular exposure.

WEB 1394 Rev F